SynthesisFrontiers in pharmacology2020
Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- Potential benefits ofFrontiers in nutrition · 2025Pooled it
- Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Factors associated with inflammatory cytokines in family caregivers of allogeneic hematopoietic stem cell transplantation (HSCT) recipients.Brain, behavior, and immunity · 2025Trial
- Restoration of circadian rhythm as novel targets against sarcopenia.Chinese medical journal · 2026Review
- GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?Rheumatology international · 2026Review
- Dysfunctional adipose tissue-lymphatic crosstalk in obesity.Nature reviews. Endocrinology · 2026Review
- Eating and Mental Health Disorders.Nutrients · 2026Article
- The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.Nature reviews. Rheumatology · 2026Review
- Pulmonary toxicity of polymethyl methacrylate nanoplastics via intratracheal intubation in mice.Scientific reports · 2026Article
- Adalimumab Reduces Epicardial Adipose Tissue in Psoriasis: A Post Hoc Analysis of a Randomized Placebo-Controlled Clinical Trial.Psoriasis (Auckland, N.Z.) · 2026Article
- Changes in weight associated with tumor necrosis factor inhibition in psoriatic arthritis: results from a retrospective cohort study.Clinical rheumatology · 2025Article
- Weighing the Consequences: Can Patients with Inflammatory Bowel Disease Jump on the GLP-1 Bandwagon?Digestive diseases and sciences · 2025Article
- Genetic associations between orexin genes and phenotypes related to behavioral regulation in humans, including substance use.Molecular psychiatry · 2025Article
- Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.Current opinion in rheumatology · 2025Review
- Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2025Article
- Advances in Leaf Plant Bioactive Compounds: Modulation of Chronic Inflammation Related to Obesity.International journal of molecular sciences · 2025Review
- The Role of Inflammatory Markers in Linking Metabolic Syndrome to Cognitive Decline in Middle-Aged Women: A Focus on TNF-α and IL-6.Metabolites · 2025Article
- Genetic interaction between oxidative stress and body mass index in a Spanish population.Redox biology · 2025Article
- Serum levels of Wnt5a in Egyptian women with obesity and their association with toll like receptor 2 Arg753Gln gene polymorphism in a pilot case control study of obesity as a state of metaflammation.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this systematic review and meta-analysis of longitudinal studies was to ascertain to effects of TNF-α inhibitor therapy on body weight and BMI.
methodsThree databases (PubMed, OVID, and EMBASE) were systematically searched from inception to August 2018. We identified prospective, retrospective, and randomized controlled studies in adults with immune-mediated inflammatory diseases treated with TNF-α inhibitors based on pre-specified inclusion criteria. A random-effects model was used to estimate standardised mean change (SMCC).
resultsTwenty-six longitudinal studies with a total of 1,245 participants were included in the meta-analysis. We found evidence for a small increase in body weight (SMCC = 0.24, p = .0006, 95% CI [0.10, 0.37]) and in BMI (SMCC = 0.26, p < .0001, 95% CI [0.13, 0.39]). On average, patients gained 0.90kg (SD = 5.13) under infliximab, 2.34kg (D = 5.65) under etanercept and 2.27kg (SD = 4.69) during treatment with adalimumab within the duration of the respective studies (4-104 weeks).
conclusionOur results yield further support the for the view that TNF-α inhibitors increase body weight and BMI as a potential side effect. Modulating cytokine signaling could be a future therapeutic mechanism to treat disorders associated with weight changes such as anorexia nervosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.